Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cladribine+Venetoclax After Failure of Venetoclax+Hypomethylating Agent in Monocytic AML
NCT06232655Phase 2Active, not recruiting
- Sponsor
- University of Colorado Denver
- Start
- Feb 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cladribine in acute myeloid leukemia (AML) (2 arms), sponsored by University of Colorado Denver. Primary endpoint: Overall Response Rate at 6 months. Started Feb 2024; status: active, not recruiting.
02
Drugs
cladribine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06232655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06232655.